215 related articles for article (PubMed ID: 33500573)
41. [Predictive biomarkers for tumor-relevant signaling pathways in molecular pathology].
Bonzheim I; Fend F
Pathologe; 2014 Feb; 35(1):93-105. PubMed ID: 24496994
[TBL] [Abstract][Full Text] [Related]
42. Biden time.
Nature; 2016 Apr; 532(7600):414. PubMed ID: 27121803
[No Abstract] [Full Text] [Related]
43. The Changing Face of Oncology Research, Drug Development, and Clinical Practice: Toward Patient-Focused Precision Therapeutics.
Venkatakrishnan K; van der Graaf PH; Holstein SA
Clin Pharmacol Ther; 2020 Sep; 108(3):399-404. PubMed ID: 33439492
[No Abstract] [Full Text] [Related]
44. Synthetic Lethality: From Research to Precision Cancer Nanomedicine.
Gupta A; Ahmad A; Dar AI; Khan R
Curr Cancer Drug Targets; 2018; 18(4):337-346. PubMed ID: 28669337
[TBL] [Abstract][Full Text] [Related]
45. Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.
Robichaux JP; Elamin YY; Vijayan RSK; Nilsson MB; Hu L; He J; Zhang F; Pisegna M; Poteete A; Sun H; Li S; Chen T; Han H; Negrao MV; Ahnert JR; Diao L; Wang J; Le X; Meric-Bernstam F; Routbort M; Roeck B; Yang Z; Raymond VM; Lanman RB; Frampton GM; Miller VA; Schrock AB; Albacker LA; Wong KK; Cross JB; Heymach JV
Cancer Cell; 2019 Oct; 36(4):444-457.e7. PubMed ID: 31588020
[TBL] [Abstract][Full Text] [Related]
46. Engineering Tumor Hypersusceptibility to Checkpoint Immunotherapy.
Fernández A
Trends Cancer; 2017 Oct; 3(10):675-677. PubMed ID: 28958385
[TBL] [Abstract][Full Text] [Related]
47. Editorial overview: cancer: from target discovery to targeted therapy: the risky business of target validation.
Cruzalegui F
Curr Opin Pharmacol; 2014 Aug; 17():iv-vi. PubMed ID: 25220882
[No Abstract] [Full Text] [Related]
48. [SUMMIT: a basket study scores points].
Luscan A; Pasmant É
Med Sci (Paris); 2018 Nov; 34(11):910-913. PubMed ID: 30526831
[No Abstract] [Full Text] [Related]
49. Challenges ahead for companion diagnostics.
Schmidt C
J Natl Cancer Inst; 2012 Jan; 104(1):14-5. PubMed ID: 22173588
[No Abstract] [Full Text] [Related]
50. Translating cancer research into targeted therapeutics.
de Bono JS; Ashworth A
Nature; 2010 Sep; 467(7315):543-9. PubMed ID: 20882008
[TBL] [Abstract][Full Text] [Related]
51. When Tissue Is No Longer the Issue: Tissue-Agnostic Cancer Therapy Comes of Age.
Luoh SW; Flaherty KT
Ann Intern Med; 2018 Aug; 169(4):233-239. PubMed ID: 30073297
[TBL] [Abstract][Full Text] [Related]
52. New developments on targeted cancer therapy: Multi-faceted issues in targeted cancer therapy.
Bao J; Qiao L
Cancer Lett; 2017 Feb; 387():1-2. PubMed ID: 28038727
[No Abstract] [Full Text] [Related]
53. Beyond the limitation of targeted therapy: Improve the application of targeted drugs combining genomic data with machine learning.
Miao R; Chen HH; Dang Q; Xia LY; Yang ZY; He MF; Hao ZF; Liang Y
Pharmacol Res; 2020 Sep; 159():104932. PubMed ID: 32473309
[TBL] [Abstract][Full Text] [Related]
54. From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.
Adashek JJ; Subbiah V; Kurzrock R
Trends Cancer; 2021 Jan; 7(1):15-28. PubMed ID: 33008795
[TBL] [Abstract][Full Text] [Related]
55. A Precision Medicine Approach to Clinical Trials.
Rubin R
JAMA; 2016 Nov; 316(19):1953-1955. PubMed ID: 27760248
[No Abstract] [Full Text] [Related]
56. Precision cancer medicine: the future is now, only better.
Tsimberidou AM; Eggermont AM; Schilsky RL
Am Soc Clin Oncol Educ Book; 2014; ():61-9. PubMed ID: 24857061
[TBL] [Abstract][Full Text] [Related]
57. Session 2: Mutational discordance: the big challenge in personalized treatments - any solutions?
Siddiqui M; Chand M; Eng C; Mehdizadeh A; Mirnezami A; Brown G
Colorectal Dis; 2018 May; 20 Suppl 1():49-51. PubMed ID: 29878676
[TBL] [Abstract][Full Text] [Related]
58. Yale Cancer Center Precision Medicine Tumor Board: new technology, new drugs, and the value of repeat testing.
Hafez N; Walther Z; Eder JP; Sklar JL; Gettinger SN; Finberg KE; Goldberg SB
Lancet Oncol; 2020 Mar; 21(3):343-344. PubMed ID: 32950226
[No Abstract] [Full Text] [Related]
59. Scientists Journey Into Genomes Via CRISPR-Cas9.
Ricks D
J Natl Cancer Inst; 2015 Nov; 107(11):djv352. PubMed ID: 26538621
[No Abstract] [Full Text] [Related]
60. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.
Coyne GO; Takebe N; Chen AP
Curr Probl Cancer; 2017; 41(3):182-193. PubMed ID: 28372823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
